title: CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis.
authors.affiliation: Ludwig Center for Cancer Research of the University of Lausanne, Switzerland camilla.Jandus@chuv.ch sara.trabanelli@gmail.com.
authors.forename: Sara
authors.initials: S
authors.lastname: Trabanelli
authors.affiliation: Department of Specialistic, Diagnostic and Experimental Medicine, Institute of Hematology "Seràgnoli", University of Bologna, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Curti
authors.affiliation: Department of Specialistic, Diagnostic and Experimental Medicine, Institute of Hematology "Seràgnoli", University of Bologna, Italy.
authors.forename: Mariangela
authors.initials: M
authors.lastname: Lecciso
authors.affiliation: Ludwig Center for Cancer Research of the University of Lausanne, Switzerland.
authors.forename: Bérengère
authors.initials: B
authors.lastname: Salomé
authors.affiliation: Tumor Immunology, Department of Clinical Research, University of Bern, Switzerland.
authors.forename: Carsten
authors.initials: C
authors.lastname: Riether
authors.affiliation: Tumor Immunology, Department of Clinical Research, University of Bern, Switzerland Department of Medical Oncology, Inselspital, Bern University Hospital and University of Bern, Switzerland.
authors.forename: Adrian
authors.initials: A
authors.lastname: Ochsenbein
authors.affiliation: Ludwig Center for Cancer Research of the University of Lausanne, Switzerland.
authors.forename: Pedro
authors.initials: P
authors.lastname: Romero
authors.affiliation: Ludwig Center for Cancer Research of the University of Lausanne, Switzerland camilla.Jandus@chuv.ch sara.trabanelli@gmail.com.
authors.forename: Camilla
authors.initials: C
authors.lastname: Jandus
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D019070:Cell Lineage / Q000187:drug effects / Q000276:immunology*; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D015870:Gene Expression; D006801:Humans; D007113:Immunity, Innate; D016130:Immunophenotyping; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D053699:Interleukin-7 Receptor alpha Subunit / Q000235:genetics / Q000276:immunology*; D007378:Interleukins / Q000096:biosynthesis / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D008214:Lymphocytes / Q000145:classification / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D053699:Interleukin-7 Receptor alpha Subunit; D007378:Interleukins; D014409:Tumor Necrosis Factor-alpha; D003561:Cytarabine; D007371:Interferon-gamma; D003630:Daunorubicin
keywords: CD127+ ILCs; acute myeloid leukemia; dysregulated; innate lymphoid cells; treatment naive